Module

Lymphomas and Hodgkin's Disease

Source: Lymphoma Annual Update 2005

Lymphomas and Hodgkin's Disease

Program Director: Julie M. Vose, MD

Faculty:

Frederick B. Hagemeister, MD

CREDIT INFORMATION

Release Date: October 14, 2005

Expiration Date: October 13, 2006

Physicians: maximum of 1.0 AMA PRA Category 1 Credit™

Registered Nurses: 1.3 Nursing contact hours

Status: The activity is not currently available for credit.

Learning Objectives

Upon completion of this activity, participants should be able to:

Review results of recent clinical trials for early-stage and advanced Hodgkin's lymphoma.
Evaluate efficacy and safety of currently available therapy for Hodgkin's lymphoma.
Describe strategies for management of relapsed Hodgkin's lymphoma, including treatment complications.

Topics covered include:

Introduction--Long-Term Treatment of Hodgkin's Lymphoma
Classification of Hodgkin's Lymphoma
Treatment of Early-Stage HL: ABVD Plus Radiation
Treatment of Early-Stage HL: Chemotherapy Alone
Classification of Early-Stage HL with Poor Prognostic Features
Treatment of Poor Prognosis Early-Stage HL
Prognostic Factors for Advanced HL
Treatment for Advanced HL
Radiation for Advanced HL
Treatment of Relapsed HL
Autologous Stem Cell Transplantation for Relapsed HL
Prognostic Factors for Autologous Stem Cell Transplantation
Novel Autologous Stem Cell Transplantation Programs
New Single or Combination Therapies for Relapsed HL
Complications of Therapy for HL
Summary Future Directions in HL

Disclaimer: The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.